X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1. It is being investigated in combination with immune checkpoint inhibitors in first line small cell lung cancer patients with extensive disease.
Lead Product(s): Iadademstat,Durvalumab
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1 with powerful differentiating effect in hematologic cancer. It is being investigated in with gilteritinib for relapsed/refractory AML harboring a FMS-like tyrosine kinase mutation.
Lead Product(s): Iadademstat,Gilteritinib Fumarate
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
ORY-1001 (Iadademstat) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers
Lead Product(s): Iadademstat,Paclitaxel
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
ORY-1001 (iadademstat) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers.
Lead Product(s): Iadademstat,Undisclosed
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eurostars
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Funding December 16, 2022
Details:
ORY-1001 (iadademstat) is an orally active, highly potent and selective inhibitor of the epigenetic enzyme LSD1, currently under clinical development for the treatment of hematologic cancers and certain solid tumors.
Lead Product(s): Iadademstat
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
Under the terms of the agreement, Oryzon and the NCI will collaborate on potential further clinical development of Oryzon’s clinical stage LSD1 inhibitor, iadademstat, in different types of solid and hematological cancers.
Lead Product(s): Iadademstat,Paclitaxel
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 19, 2022
Details:
Evidence of clinical efficacy continues to be robust and consistent with previously reported data for ORY-1001 (Iadademstat), with an objective response rate (ORR) of 81% (22 of 27 evaluable patients); of these, 64% were complete remissions and 36% partial remissions.
Lead Product(s): Iadademstat,Azacitidine
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
Iadademstat (ORY-1001), is an oral, highly potent and selective inhibitor of the epigenetic enzyme LSD1, a chromatin remodeler that interacts with a variety of transcription factors involved in SCLC, other solid tumors and hematological cancers such as acute myeloid leukemia.
Lead Product(s): Iadademstat,Paclitaxel
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
The funding is for Oryzon’s project, Iadademstat (ORY-1001) a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers.
Lead Product(s): Iadademstat,Azacitidine
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Commission
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 07, 2022
Details:
The net proceeds will be used to evaluate efficacy and optimal dose of ORY-1001 (iadademstat), a novel, highly potent, and selective inhibitor of LSD1, plus Xospata (gilteritinib), an inhibitor of FLT3, in patients with relapsed/refractory AML with FLT3 mutations.
Lead Product(s): Iadademstat,Gilteritinib Fumarate
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Commission
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 07, 2022
Details:
ORY-1001 (Iadademstat), small oral molecule, act as a highly selective inhibitor of the epigenetic enzyme LSD1 has a powerful differentiating effect in hematologic cancers, combination of iadademstat with gilteritinib demonstrated a very strong synergy in preclinical models.
Lead Product(s): Iadademstat,Gilteritinib Fumarate
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
The combination of iadademstat with azacitidine continues to show a good safety profile, with only two serious adverse events reported as probably related to treatment.
Lead Product(s): Iadademstat,Azacitidine
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2021
Details:
Iadademstat (ORY-1001) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers. Robust signals of clinical efficacy, with ORR of 83%, of which 67% are CR/CRi.
Lead Product(s): Iadademstat,Azacitidine
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
A first in man Phase I/IIa clinical trial with iadademstat in refractory and relapsed acute leukemia patients demonstrated safety and good tolerability of the drug.
Lead Product(s): Iadademstat
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2021
Details:
Iadademstat is an investigational, oral, small molecule covalent inhibitor of the epigenetic enzyme LSD1, a chromatin remodeler that interacts with a variety of transcription factors involved in leukemia and other cancers.
Lead Product(s): Iadademstat,Azacitidine
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2021
Details:
The results obtained so far suggest that the therapeutic efficacy between the two iadademstat doses used in the study is equivalent, with current ORRs of 85% at 90 ug/sqm/d and 83% at 60 ug/sqm/d.
Lead Product(s): Iadademstat,Azacitidine
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
ALICE is a single arm, open-label Phase IIa clinical trial to evaluate the safety, tolerability, dose finding and efficacy of iadademstat in combination with azacitidine in older patients with Acute Myeloid Leukemia (AML) in first line therapy.
Lead Product(s): Iadademstat,Azacitidine
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
The article describes the firstin- human clinical trial in acute myeloid leukemia (AML) patients with iadademstat (ORY-1001), the most potent and selective KDM1A inhibitor to date. Data support safety of the drug in elderly patients with acute leukemia .
Lead Product(s): Iadademstat,Azacitidine
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
The combination of the three agents, iadademstat and carboplatin-etoposide, produced encouraging signs of clinical efficacy, with an objective response rate (ORR) of 40% (4 partial remissions in 10 patients) and a mean duration of response of 4.5 months.
Lead Product(s): Iadademstat,Carboplatin,Etoposide
Therapeutic Area: Oncology Product Name: ORY-1001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
ALICE is a single arm, open-label Phase IIa clinical trial to evaluate the safety, tolerability, dose finding and efficacy of iadademstat in combination with azacitidine in older patients with AML in first line therapy.
Lead Product(s): Iadademstat,Azacitidine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
